Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.